A smart inhaler is only as good as the numbers it records. RS01X measures inhalation duration, volume and peak inspiratory flow. Those readings help build a picture of use and technique, so the first question a pharmaceutical or clinical partner should ask is a simple one: are they accurate?
A study set out to answer it: first presented at the Respiratory Drug Delivery (RDD) 2024 conference, then published, peer-reviewed, in the International Journal of Chronic Obstructive Pulmonary Disease. Researchers compared RS01X's on-device readings against an external inhalation-profile recorder, the laboratory reference for this kind of measurement, across 97 participants: 32 with asthma, 30 with COPD and 35 with healthy lungs, over 291 inhalations.
Agreement between the device and the reference was near-perfect: an intraclass correlation above 0.95 for every parameter measured (duration, volume and peak inspiratory flow), all highly significant. The only meaningful differences appeared when participants deliberately used the inhaler incorrectly, holding it at an angle rather than level, and RS01X registered that too.
Why measurement accuracy is the foundation
This study validates measurement accuracy, rather than patient outcomes. For partners building an evidence programme, reliable readings are the starting point: the inhalation data behind technique feedback, adherence analysis and real-world evidence.
"Connected care only works if the measurements underneath it are trustworthy. An independent validation like this is the part you have to get right before anything built on the data means anything."
Martijn Grinovero, Chief Commercial Officer, Amiko
RS01X keeps the proven RS01 mechanism and builds Respiro's sensing around it. The study shows how closely its duration, volume and peak-flow readings agree with a laboratory reference. Find the full study and the wider research record on our evidence page.
Source: Chamaon D, Sportel E, Elferink ECM, van der Palen J. Validation of an AI-Powered Smart Dry Powder Inhaler (RS01X) for Asthma and COPD in a Clinical Setting. Int J Chron Obstruct Pulmon Dis. 2025;20:811–819. doi:10.2147/COPD.S490684. Peer-reviewed; n=97. The findings were first presented at Respiratory Drug Delivery (RDD) 2024 and published in peer-reviewed form in 2025. This study validated the accuracy of the device's measurements; it is not a claim of treatment efficacy or individual outcomes.